1. YB-1 Oncoprotein Controls PI3K/Akt Pathway by Reducing Pten Protein Level
- Author
-
Alessandra Pollice, Eleonora Montuori, Tiziana Angrisano, Viola Calabrò, Antonella Delicato, Delicato, A., Montuori, E., Angrisano, T., Pollice, A., and Calabro, V.
- Subjects
Cell signaling ,PTEN ,QH426-470 ,YB-1 ,Phosphatidylinositol 3-Kinases ,HEK293 Cell ,Genetics ,Gene silencing ,HaCaT Cell ,HaCaT Cells ,Humans ,Genetics (clinical) ,PI3K/AKT/mTOR pathway ,biology ,Chemistry ,Brief Report ,HEK 293 cells ,PTEN Phosphohydrolase ,Subcellular localization ,Cell biology ,HEK293 Cells ,proteasome ,Proteasome ,PI3K/Akt pathway ,Cancer cell ,biology.protein ,Y-Box-Binding Protein 1 ,Phosphatidylinositol 3-Kinase ,cold-shock proteins ,Cold-shock protein ,Proto-Oncogene Proteins c-akt ,Human ,Signal Transduction - Abstract
YB-1 is a multifunctional protein overexpressed in many types of cancer. It is a crucial oncoprotein that regulates cancer cell progression and proliferation. Ubiquitously expressed in human cells, YB-1 protein functions are strictly dependent on its subcellular localization. In the cytoplasm, where YB-1 is primarily localized, it regulates mRNA translation and stability. However, in response to stress stimuli and activation of PI3K and RSK signaling, YB-1 moves to the nucleus acting as a prosurvival factor. YB-1 is reported to regulate many cellular signaling pathways in different types of malignancies. Furthermore, several observations also suggest that YB-1 is a sensor of oxidative stress and DNA damage. Here we show that YB-1 reduces PTEN intracellular levels thus leading to PI3K/Akt pathway activation. Remarkably, PTEN reduction mediated by YB-1 overexpression can be observed in human immortalized keratinocytes and HEK293T cells and cannot be reversed by proteasome inhibition. Real-time PCR data indicate that YB-1 silencing up-regulates the PTEN mRNA level. Collectively, these observations indicate that YB-1 negatively controls PTEN at the transcript level and its overexpression could confer survival and proliferative advantage to PTEN proficient cancer cells.
- Published
- 2021